P. Emanuel

发表

PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia.

Jingliao Zhang, Zhifu Xiang, Priyangi A. Malaviarachchi, 2018, Cellular signalling.

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

R. Larson, Z. Estrov, J. Keck, 2009, Journal of hematology & oncology.

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

P. Emanuel, R. Castleberry, R. Snyder, 2000, Blood.

Key Clinical Message

S. Schichman, V. Kaur, Zhifu Xiang, 2022 .

Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia

P. Emanuel, Y. L. Liu, S. Meleth, 2005, Pediatric blood & cancer.

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia

P. Emanuel, 2008, Leukemia.

Familial and congenital polycythemia in three unrelated families.

C. Eaves, A. D’Andrea, V. Broudy, 1992, Blood.

Familial and congenital polycythemia in three unrelated families.

C. Eaves, A. D’Andrea, V. Broudy, 1992 .

Conformationally defined retinoic acid analogues. 4. Potential new agents for acute promyelocytic and juvenile myelomonocytic leukemias.

M. Taimi, P. Emanuel, G. Chen, 1998, Journal of medicinal chemistry.

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.

M. Loh, J. Issa, C. Mullighan, 2009, Blood.

A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial

J. Radich, R. Larson, F. Appelbaum, 2010 .

Myelodysplastic syndromes clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

RAS Pathway Mutations in Juvenile Myelomonocytic Leukemia

P. Emanuel, 2008, Acta Haematologica.

Mutations of the NF 1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis , Type 1

K. Shannon, L. Side, P. Emanuel, 1998 .

Myelodysplasia and myeloproliferative disorders in childhood: an update

P. Emanuel, 1999, British journal of haematology.

Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.

K. Shannon, P. Emanuel, R. Castleberry, 1996, Molecular medicine today.

Chronic myelogenous leukemia.

J. Radich, P. Greenberg, K. Bhalla, 2004, Journal of the National Comprehensive Cancer Network : JNCCN.

Urticaria pigmentosa and preleukemia: evidence for reactive mast cell proliferation.

P. Emanuel, J. Barton, W. M. Sams, 1991, Journal of the American Academy of Dermatology.

MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia.

P. Papenhausen, S. Schichman, Zhifu Xiang, 2015, Cancer genetics.

Valproic acid-induced cytopenias: evidence for a dose-related suppression of hematopoiesis.

P. Emanuel, T. Howard, K. Zuckerman, 1990, The Journal of pediatrics.

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.

Shaoguang Li, S. Lensing, Zhifu Xiang, 2016, Blood.

MYELOID NEOPLASIA Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia

John R. Haliburton, M. Loh, A. Abate, 2014 .

Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia

M. Loh, P. Emanuel, Y. L. Liu, 2013, Leukemia.

Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

P. Emanuel, K. Zuckerman, R. Castleberry, 1991, Blood.

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

M. Loh, B. Gelb, M. Tartaglia, 2005, Blood.

In Vitro Regulation of Colony Stimulating Factor-Mediated Hematopoiesis in Healthy Individuals and Patients with Different Types of Myeloproliferative Disease

C. Niemeyer, P. Emanuel, T. Vraetz, 2003 .

Human Herpesvirus 6 Infection Mimicking Juvenile Myelomonocytic Leukemia in an Infant

P. Emanuel, A. Lorenzana, D. Carrigan, 2002, Journal of pediatric hematology/oncology.

A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia.

P. Emanuel, A. Homans, R. Castleberry, 1994, The New England journal of medicine.

Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia.

P. Emanuel, S. Clark, S. Clark, 1989, Blood.

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

M. Loh, A. Yoshimi, C. Niemeyer, 2006, Blood.

Mixed myeloproliferative and myelodysplastic disorders

P. Emanuel, 2007, Current hematologic malignancy reports.

The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia.

P. Emanuel, R. Castleberry, R. Gualtieri, 1991, Experimental hematology.

Proteasome‐associated autoinflammatory syndromes: advances in pathogeneses, clinical presentations, diagnosis, and management

P. Emanuel, M. Kessler, A. McDermott, 2015, International journal of dermatology.

Juvenile myelomonocytic leukemia.

P. Emanuel, 2004, Current hematology reports.

Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects

I. Makhoul, L. Hutchins, E. Siegel, 2017, Oncotarget.

M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion.

I. Bernstein, P. Emanuel, Y. L. Liu, 2018, Blood advances.

Cloning and sequencing of the cDNAs encoding two alternative splicing-derived variants of the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor.

P. Emanuel, K. Zuckerman, X. Hu, 1994, Biochimica et biophysica acta.

Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis.

M. Arcasoy, S. Burns, P. Emanuel, 2002, Blood.

myelomonocytic leukemia cell growth Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile

P. Iversen, P. Emanuel, M. Sioud, 2013 .

Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth.

P. Iversen, P. Emanuel, M. Sioud, 2002, Blood.

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

M. Loh, B. Widemann, P. Emanuel, 2005 .

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.

M. Loh, K. Shannon, P. Emanuel, 2013, Blood.

are rare in juvenile myelomonocytic leukemia GATA2 Mutations in

M. Loh, P. Emanuel, Y. L. Liu, 2014 .

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.

M. Loh, M. L. Le Beau, S. Meshinchi, 2004, Blood.

Atypical cellular disorders.

R. Arceci, B. Longley, P. Emanuel, 2002, Hematology. American Society of Hematology. Education Program.

Chronic myelogenous leukemia.

J. Radich, P. Greenberg, K. Bhalla, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Sustained fetal hematopoiesis causes juvenile death from leukemia: evidence from a dual-age-specific mouse model.

Erich A. Peterson, D. Johann, S. Lensing, 2020, Blood advances.

Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells

K. Weinberg, R. Seeger, P. Emanuel, 2003, Leukemia.

The 5′‐untranslated RNA of the human dhfr minor transcript alters transcription pre‐initiation complex assembly at the major (core) promoter

Kedar Shrestha, P. Emanuel, Zheng Meng, 2003, Journal of cellular biochemistry.

Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

K. Shannon, L. Side, P. Emanuel, 1998, Blood.

mrtl—A translation/localization regulatory protein encoded within the human c‐myc locus and distributed throughout the endoplasmic and nucleoplasmic reticular network

P. Emanuel, Y. L. Liu, Hyoungsoo Choi, 2008, Journal of cellular biochemistry.

Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript.

J. Ruppert, W. Grizzle, P. Emanuel, 2003, Experimental cell research.

Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

R. Foà, B. Gelb, C. Schoch, 2006, American journal of human genetics.

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

J. Radich, R. Larson, M. Slovak, 2014, British journal of haematology.

The Genomic Landscape of Juvenile Myelomonocytic Leukemia

T. Golub, M. Loh, G. Getz, 2015, Nature Genetics.

Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

John R. Haliburton, M. Loh, A. Abate, 2015, Blood.

Myelodysplastic / myeloproliferative diseases as classified by the World Health Organization Chronic myelomonocytic leukemia Atypical chronic myeloid leukemia Juvenile myelomonocytic leukemia

P. Emanuel, 2022 .

Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.

M. L. Le Beau, K. Shannon, K. Stephens, 2006, Blood.

PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.

P. Emanuel, R. Castleberry, Yunying Liu, 2009, Leukemia research.

MOLECULAR TARGETS FOR THERAPY (MTT)

K. Weinberg, R. Seeger, P. Emanuel, 2003 .

Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

M. Loh, R. Arceci, T. Alonzo, 2015, Pediatric blood & cancer.

Hallway gossip between Ras and PI3K pathways.

P. Emanuel, 2014, Blood.

Author's response to the comments on “PTEN deficiency is a common defect in juvenile myelomonocytic leukemia” [Leuk. Res. (2008) (Epub November 17)]

P. Emanuel, Y. L. Liu, R. Castleberry, 2009 .

A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.

Suzanne Kamel-Reid, Peter Emanuel, J. Radich, 2012, Blood.

Alterations in RNA‐binding activities of IRES‐regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF‐IR translational control in human breast tumor cells

P. Emanuel, P. King, N. Jackson, 2008, Journal of cellular physiology.

The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation

P. Emanuel, L. Nabors, P. King, 2005, Nucleic acids research.

Development of mouse hybridomas for production of monoclonal antibodies specific to Burkholderia mallei and Burkholderia pseudomallei.

P. Emanuel, Shien Tsai, S. Lo, 2006, Hybridoma.

Moving a Carbohydrate Mimetic Peptide into the clinic

I. Makhoul, L. Hutchins, E. Siegel, 2015, Human vaccines & immunotherapeutics.

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

P. Emanuel, Y. L. Liu, R. Castleberry, 2004 .

Juvenile chronic myelogenous leukemia.

J. Hess, P. Emanuel, R. Castleberry, 1996, American journal of clinical pathology.

PTEN transcript variants caused by illegitimate splicing in “aged” blood samples and EBV-transformed cell lines

Priyangi A. Malaviarachchi, P. Emanuel, M. Beggs, 2010, Human Genetics.

A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy

V. Kaur, P. Emanuel, Y. Jethava, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

PTEN transcript variants caused by illegitimate splicing in “aged” blood samples and EBV-transformed cell lines

Priyangi A. Malaviarachchi, P. Emanuel, M. Beggs, 2010, Human Genetics.

A case of proteasome-associated auto-inflammatory syndrome with compound heterozygous mutations.

P. Emanuel, Yin Liu, R. Goldbach-Mansky, 2013, Journal of the American Academy of Dermatology.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Z. Estrov, H. Burris, K. Patel, 2004 .

Correction: Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia

T. Golub, M. Loh, G. Getz, 2016, Nature Genetics.

Evidence for differential ribonucleoprotein complex assembly in vitro on the 5′-untranslated region of the human IGF-IR transcript

P. Emanuel, R. Snyder, K. Shrestha, 2003, Molecular and Cellular Endocrinology.

cell erythropoiesis mutant Epo (R103A), a specific inhibitor of human primary hematopoietic Purification and characterization of the yeast-expressed erythropoietin

M. Arcasoy, S. Burns, P. Emanuel, 2013 .

Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1.

K. Shannon, L. Side, P. Emanuel, 1997 .

cell erythropoiesis mutant Epo (R103A), a specific inhibitor of human primary hematopoietic Purification and characterization of the yeast-expressed erythropoietin

M. Arcasoy, S. Burns, P. Emanuel, 2013 .

Drifting precariously due to lost tyrosines

P. Emanuel, 2007 .

Timing of the Loss of Pten Is Critical in Determining the Disease Phenotype in Mice- a Mouse Model for Pediatric Mixed MDS/MPN

Shaoguang Li, S. Lensing, Zhifu Xiang, 2014 .